Cancer treatment can be financially punishing long before a patient completes a course of medicines. The cost of a drug, the price printed on its pack and the amount ultimately charged by a hospital can be very different. For families already coping with the physical and emotional strain of cancer, understanding these differences is not an academic exercise. It can determine whether treatment remains affordable.
A new round of government-directed price revisions promises relief for patients buying several anti-cancer medicines. Yet the revised prices also expose a limitation in the way affordability is measured: reducing the price of some medicines does not necessarily make the most expensive treatments accessible, nor does it settle questions about the mark-ups added along the healthcare supply chain.
The issue has gained urgency following two developments. The National Pharmaceutical Pricing Authority (NPPA) has published revised maximum retail prices (MRPs) for non-scheduled anti-cancer medicines, with the new prices due to take effect on November 9, 2026. Separately, the Supreme Court has questioned the Centre and private hospitals over medicine pricing and the large gaps between procurement costs and the amounts charged to patients.
Together, these developments raise a larger question: can medicine price controls deliver meaningful relief if substantial costs remain outside their reach?
Sharp cuts, but not across the board
The NPPA’s revised price list, based on information received from companies up to October 28, 2026, shows that the impact varies considerably between products. Some generic cancer medicines face substantial reductions, while the listed prices of several high-cost patented brands remain unchanged. The list is an important record of the price revisions, but it should not be mistaken for a measure of what every patient will save on an entire course of treatment.
The difference is striking in the examples reported by The Economic Times and its pharmaceutical industry publication, ETPharma. Their reporting identifies Keytruda, a pembrolizumab injection marketed by MSD, among the high-priced medicines whose MRP remains unchanged. The revised list puts its 100 mg injection at ₹2,16,500 per vial. Tagrisso, an osimertinib treatment marketed by AstraZeneca, is also unchanged at ₹4,16,492.48 for a pack of 30 tablets.
These figures do not, by themselves, establish what a particular patient will pay after discounts, assistance programmes or hospital billing arrangements. Nor does an unchanged MRP automatically establish that a price is unlawful. They do, however, illustrate the limits of a price revision when some of the costliest products see no reduction in their listed retail prices.
The contrast with selected generic products is substantial. In the NPPA list, Mylan’s MyTera, an abiraterone acetate 250 mg tablet pack of 120, falls from ₹16,865 to ₹5,105.50 — a reduction of about 69.7%. Khandelwal Laboratories’ ABIRAT, containing the same active ingredient and pack size, falls from ₹36,088.81 to ₹4,064.48, a reduction of about 88.7%.
These examples show the potential for meaningful savings. They also underline why comparisons must be made carefully: brands containing the same active ingredient can start from very different MRPs, and the price of a pack is not the same as the total cost of treatment. Patients should discuss suitable alternatives with their treating doctors rather than switch medicines on price alone.
What does a price cap actually control?
The latest intervention concerns trade margins on 137 non-scheduled anti-cancer medicines, with the government setting a 30% cap and directing revised MRPs for covered formulations. The distinction between scheduled and non-scheduled medicines matters because the regulatory mechanisms are not identical.
In its March 2026 statement, the Department of Pharmaceuticals said that ceiling prices for 131 anti-cancer drugs had resulted in an average reduction of around 21% against the prices fixed under the National List of Essential Medicines, with estimated annual savings of approximately ₹294 crore. The government also pointed to subsidised treatment in public hospitals, the Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana scheme, Jan Aushadhi outlets and AMRIT pharmacies as other routes to improving access. These are government-reported figures and measures; they do not establish the savings experienced by every household.
A trade-margin cap and a ceiling on the price of a medicine are not interchangeable. A margin cap seeks to limit the difference permitted within the distribution chain under the relevant framework. It does not necessarily mean that the underlying price charged by a manufacturer will fall by the same proportion. This distinction is particularly important for patented medicines, where the scope for reducing a final price may differ from that for generic products facing competition.
The policy’s impact must therefore be judged product by product. It is too early to conclude that the latest revisions have failed: they are due to take effect on 9 November. But the unchanged prices in the list make it equally difficult to claim that the measure will make all high-cost cancer treatment affordable.
The hospital bill is a separate challenge
The Supreme Court’s hearing on October 27, 2026, brought another part of the problem into focus: the difference between the price at which medicines or medical consumables are procured and the amount charged to patients.
According to reports by Moneycontrol and IANS, the bench questioned the Centre over the regulatory framework and cited an example of a drip line bought for ₹15 but billed to a patient at ₹250. The court also heard an account involving a cancer injection that a medical distributor said could be procured for ₹11,000 but was reportedly charged at ₹1.30 lakh by a hospital.
These were examples raised during proceedings, not evidence that every hospital applies comparable mark-ups. Hospital representatives argued that institutions must maintain round-the-clock facilities, ensure the quality of medicines and cover operating expenses. The bench questioned whether such costs justified steep differences in medicine prices and remarked that hospitals could not survive through “dacoity”.
The court reserved its verdict. Its observations should not be presented as a final ruling, but they sharpen the policy question: how should legitimate healthcare costs be recovered, and how should patients be protected from excessive or poorly explained charges?
The hospital-billing issue is related to, but distinct from, the NPPA’s revised MRPs. A lower MRP may help a patient purchasing a covered medicine, but it does not automatically resolve how hospitals price medicines and consumables, or how they disclose procurement costs, discounts and charges. Equally, an unchanged MRP does not prove that a hospital’s charge is excessive. Those questions require scrutiny of the product, the transaction and the applicable rules.
Measuring affordability at the point of care
For patients, the meaningful measure of success is not simply how many prices have been revised. It is whether the medicine they need is available, whether an appropriate lower-cost alternative exists, and what they must actually pay to receive treatment.
That calls for transparent, product-level price information; clear bills that distinguish medicines from other hospital charges; effective monitoring of compliance; and accessible information about legitimate generic alternatives and patient-assistance programmes. Public procurement and institutional negotiations may also matter where expensive patented medicines remain beyond the reach of many households.
None of these measures removes the need to fund research, maintain reliable medicine supplies or operate safe hospitals. But affordability cannot be judged only from the perspective of manufacturers, distributors or healthcare providers. It must also account for household incomes and the consequences when a patient cannot meet the bill.
The NPPA’s revised list offers tangible relief on some products, and those reductions should not be dismissed. But unchanged prices for several costly brands, alongside unresolved questions about hospital mark-ups, show why a price cap is only one part of a larger response.
The real test begins when the revised prices take effect: whether the savings reach patients, whether billing practices are transparent and whether people facing cancer can obtain appropriate treatment without being pushed into financial distress. Until affordability is assessed at that point of care, lower prices on paper will remain an incomplete measure of progress.
#AffordableHealthcare #DrugPricing #CancerCare #CancerTreatment #HealthcareCosts #NPPA #MedicinePrices #HospitalBilling #PatientRights #HealthcarePolicy
No comments:
Post a Comment